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Abstract
Background: Although alterations in the methionine metabolism cycle (MMC) have been associated with vascular
complications of diabetes, there have not been consistent results about the levels of methionine and homocysteine
in type 2 diabetes mellitus (T2DM). The aim of the current study was to predict changes in plasma methionine and
homocysteine concentrations after simulated consumption of methionine-rich foods, following the development of
a mathematical model for MMC in Zucker Diabetic Fatty (ZDF) rats, as a representative T2DM animal model.
Method: The model building and simulation were performed using NONMEM® (ver. 7.3.0) assisted by Perl-Speaks-
NONMEM (PsN, ver. 4.3.0). Model parameters were derived using first-order conditional estimation method with
interactions permitted among the parameters (FOCE-INTER). NCA was conducted using Phoenix (ver. 6.4.0). For all
tests, we considered a P-value < 0.05 to reflect statistical significance.
Results: Our model featured seven compartments that considered all parts of the cycle by applying non-linear mixed
effects model. Conversion of S-adenosyl-L-homocysteine (SAH) to homocysteine increased and the metabolism of
homocysteine was reduced under diabetic conditions, and consequently homocysteine accumulated in the
elimination phase.
Using our model, we performed simulations to compare the changes in plasma methionine and homocysteine
concentrations between ZDF and normal rats, by multiple administrations of the methionine-rich diet of 1 mmol/kg,
daily for 60 days. The levels of methionine and homocysteine were elevated approximately two- and three-fold,
respectively, in ZDF rats, while there were no changes observed in the normal control rats.
Conclusion: These results can be interpreted to mean that both methionine and homocysteine will accumulate in
patients with T2DM, who regularly consume high-methionine foods.
Keywords: Methionine metabolism cycle, Homocysteine, Mathematical model, Methionine-rich diet, Type 2 diabetes
mellitus (T2DM)
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Background
The methionine metabolism cycle (MMC) plays im-
portant roles in regulating both methionine and cyst-
eine homeostasis [1], and is related with functions in
terms of cell growth and development under normal
conditions [2, 3]. As a universal key intermediate in
the MMC, homocysteine is not obtained from the
diet, but is remethylated to methionine, or converted
to cysteine by the trans-sulfuration pathway. It is
well-known that elevated homocysteine levels are
associated with the early development of cardiovascu-
lar diseases [4], especially increasing the risk in
patients with diabetes mellitus (DM) [5, 6]. A study
performed in type 1 DM (T1DM) patients revealed
an association between homocysteine levels and dia-
betic complications [7], and recent systematic review
with a meta-analysis studies concluded that high
levels of homocysteine may be associated with type 2
DM (T2DM) progression [8] and the development of
vascular complications of diabetes [9]. This is because
high blood glucose status, caused by insulin-resistance
conditions like T2DM, induces decrements of methio-
nine transmethylation, homocysteine transsulfuration,
and clearance in type 2 diabetic subjects [10], leading
to increased concentrations of plasma homocysteine
[5, 8]. On the other hand, some studies reported that
the levels of homocysteine were either reduced or
normal under diabetic conditions [11, 12]. These
inconsistent results seem to be attributable to varying
extents of hepatic and renal dysfunction [11, 13], the
methionine content of the diet [14, 15], and the clin-
ical status of diabetic disease [12, 16, 17]. Here, we
focused on the fact that a high-fat diet affects the
metabolism of both methionine and homocysteine in
a diabetic rat model [14]. Thus, 0we hypothesized
that long-term administration of a high-methionine
diet to T2DM rats with normal renal function may
create metabolic changes, culminating in an elevated
level of circulating homocysteine. To verify this hypoth-
esis, mathematical modeling of methionine metabolism
was required to predict the levels of homocysteine derived
from given amounts of methionine.
Although some earlier studies had developed several
mechanistic mathematical modeling approaches in an
effort to understand the MMC, these models specially
focused on and explained the systematic changes in cellu-
lar metabolism of methionine and homocysteine [18–20],
making it difficult to apply the theoretical predictions of
such models to real in vivo situations. Therefore, the
objective of the current study was to develop a mathemat-
ical model of the MMC using in vivo data from T2DM
rats. And we aimed to predict plasma methionine and
homocysteine concentrations using the model, following
the ingestion of a methionine-rich diet.
Methods
Study design
A single dose of 0.8 mmol/kg methionine (a mixture of L-
methionine 0.6 mmol/kg and L-methionine-d4 0.2 mmol/
kg) was given intravenously to both the Zucker diabetic
fatty (ZDF) rats (ZDF/Gmi fa/fa) [21] and the controls
(ZDF/Gmi fa/?). Blood samples were collected at 0, 10, 30,
60, 120, 210, 300, and 420 min after administration.
Methionine and homocysteine concentrations were deter-
mined using LC-ESI/MS/MS; the details of the study
design were described earlier [14].
Mechanistic modeling of the methionine metabolism
cycle (MMC)
All parameters of the MMC model were transformed to
in vivo scales, with consideration of physiological
aspects, including liver volume and systemic circulation
of methionine. The rate constants of distribution
between compartments were simplified, by reference to
prior data, suggesting that biological processes followed
generally first-order kinetics. The MMC model featured
a total of seven compartments associated with the five
compartments of methionine, homocysteine, S-adenosyl-
methionine (SAM), S-adenosyl- L-homocysteine (SAH),
cystathione, and the other two compartments addressing
systemic distribution of methionine and homocysteine
(Fig. 1). The movements of each component among
compartments were described by the following differen-
tial equations (Eq):
dA 1ð Þ=dt ¼ −KCM  A 1ð Þ þ KMC  A 2ð Þ ð1Þ
dA 2ð Þ=dt ¼ −KMS  A 2ð Þ þ KHM  A 5ð Þ−KEL
 A 2ð Þ−KMC  A 2ð Þ þ KCM  A 1ð Þ ð2Þ
dA 3ð Þ=dt ¼ KMS  A 2ð Þ−KSS  A 3ð Þ ð3Þ
dA 4ð Þ=dt ¼ KSS  A 3ð Þ−KSH  A 4ð Þ ð4Þ
dA 5ð Þ=dt ¼ KSH  A 4ð Þ−KHM  A 5ð Þ−KHC
 A 5ð Þ−KHP  A 5ð Þ þ KPH  A 7ð Þ ð5Þ
dA 6ð Þ=dt ¼ KHC  A 4ð Þ ð6Þ
dA 7ð Þ=dt ¼ −KPH  A 7ð Þ þ KHP  A 5ð Þ ð7Þ
KCM was the rate constant for the movement of
methionine from compartment 1 to 2, KMC was for move-
ment from compartment 2 to 1, and KMS from compart-
ment 2 to 3 (correspondence of methionine adenosyl
transferase [MAT]). KEL represented the rate of methionine
elimination, KSH was the transformation rate constant from
SAH to homocysteine (correspondence of SAH hydrolase
[SAHH]), KHM was the transformation rate constant from
homocysteine to methionine (corresponding to the activity
of betaine-homocysteine methyltransferase [BHMT]), and
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KHC was the transformation rate constant from homocyst-
eine to cysteine (corresponding to the activity of cystathio-
nine beta-synthase [CβS]).
Inter-individual variability (activity differences among
subjects) was explained by the exponential relationships
between the transformation rate constant from homo-
cysteine to methionine (KHM, Eq. 8) and the distribution
rate constant of homocysteine from the central to the
peripheral compartment (KHP, Eq. 9). In addition, ZDF
status was added to the MMC model as dichotomous
covariate (0 or 1), to quantify diabetic effects on rate
constants in the ZDF rats. Equations corresponding to
the above explanations were as follows:
KHM ¼ θKHM  e η1þθ1ZDFð Þ ð8Þ
KHP ¼ θKHP  e η2þθ2ZDFð Þ ð9Þ
KHC ¼ θKHC  e θ3ZDFð Þ ð10Þ
KHC ¼ θKHC  e θ4ZDFð Þ ð11Þ
Residual variability was explained by a combined error
model using both additive and proportional error (equa-
tion was not shown).
The performance of the MMC model was assessed
using graphical and numerical diagnostic tools. The
numerical analysis showed that the reduction in the ob-
jective function value (OFV) was at least 10.83 (P value
< 0.001 for one degree of freedom). Diagnostic plots,
including standard goodness-of-fit plots and graphical
assessment of the distribution of conditional weighted
residuals (CWRES), were also employed to establish
whether the MMC model was adequate for describing
the current dataset. In addition, the final model was
evaluated via visual predictive check (VPC), where we
graphically compared the original datasets and the simu-
lated results, with 95% confidence intervals (CIs), at the
5th, 50th, and 95th percentiles.
Use of the MMC model to simulate a methionine-rich diet
We assumed that methionine and homocysteine metab-
olisms were altered when T2DM patients ingested a
methionine-rich diet for 60 days. To estimate the
changes in two component levels after administration of
a methionine-rich diet, 1000 virtual datasets were gener-
ated with the aid of Monte Carlo simulations. All simu-
lated subjects were given 1 mmol/kg methionine divided
into three times daily. For methionine and homocysteine
concentrations, the simulated predicted accumulation
ratio, total area under the curves (AUC) to total duration
(AUCtotal), the AUC to 8 h (AUC0-8h), and the AUC to
the last time point (AUClast) values, were compared
between ZDF and control rats. The predicted accumula-
tion ratio was the ratio of the AUC8-16h to the AUC0-8h
(on day 1). The maximum concentration (Cmax), time to
maximum concentration (Tmax), and AUC values were
calculated via non-compartmental analysis (NCA).
Statistical analysis
The MMC model building and simulation were performed
using NONMEM® (ver. 7.3.0) assisted by Perl-Speaks-
NONMEM (PsN, ver. 4.3.0). Model parameters were
derived using first-order conditional estimation method
with interactions permitted among the parameters
(FOCE-INTER). NCA was conducted using Phoenix (ver.
Fig. 1 Schematic illustrations of Mechanistic Methionine Cycle (MMC) model
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6.4.0). For all tests, we considered a P-value < 0.05 to
reflect statistical significance.
Results
A mathematical MMC model for ZDF rats
A new mathematical MMC model was successfully de-
veloped using plasma measurements of both methionine
and homocysteine, and was characterized using seven
compartments. From the prior study [14], we found that
the plasma concentration kinetics of methionine were
similar in the ZDF and control groups, while homocyst-
eine exhibited a different kinetic pattern. Furthermore,
since the hepatic concentrations of SAM and SAH did
not differ between control and ZDF rats, the KCM, KMC,
KMS, KSS, KEL, and Vc parameters were predicted without
consideration of disease status. Changes in homocysteine
levels in the ZDF rat, the left shift of Tmax, and the
increment in Cmax, are all explained by an increment in
KSH and decrements in both KHM and KHC. The KSH
value of ZDF rats was almost 16% greater than that of
controls (ZDF versus control, 13.5 versus 11.6 h− 1).
Although the homocysteine elimination slope was
greater in ZDF rats in the early phase of elimination,
such elimination was delayed after 210 h compared with
that of controls, explained by decreases in both KHM and
KHC at this time. The final model and kinetic parameters
are shown in Table 1.
The goodness-of-fit plot for the final model showed that
the population predicted and individual predicted concen-
trations were in good agreement with the observed value.
The CWRES versus time plot was unbiased (data not
shown). The VPC plot successfully explained the plasma
concentrations of methionine and homocysteine; the 95%
CIs of the 5th, 50th, and 95th percentiles of the observa-
tional data were well-covered in the MMC model (Fig. 2).
Simulation of a methionine-rich diet
In the virtual scenario, both the methionine and homo-
cysteine levels steadily increased in ZDF rats after high-
dose methionine administration (Fig. 3). The concentra-
tions of both components steadily increased over this time
period and, after 60 days of administration, the level of
methionine in the ZDF group was twice that of controls,
triggering significant changes in the homocysteine level.
Although the accumulation ratios of methionine and
homocysteine at a dose of 0.8 mmol/kg methionine did
not differ significantly between ZDF rats and controls
(methionine in ZDF rats and controls, 1.22 and 1.10, P =
0.059; homocysteine in ZDF rats and controls, 1.23 and
2.78, P = 0.162), the ratio of homocysteine at a dose of
1 mmol/kg in ZDF rats was significantly greater than that
in controls (ZDF rats and controls, 1.21 and 1.39, P =
0.003). At 1350 h, the AUC8h of homocysteine was
307.84% greater in ZDF rats than controls (ZDF vs. con-
trol, 47.31 ± 6.06 vs. 145.64 ± 13.67; P < 0.001).
Discussion
In the current study, we aimed to develop an MMC
model using in vivo data under diabetic conditions, and
to predict the changes in methionine and homocysteine
levels after high-dose methionine administration. The
final model successfully reproduced the kinetic profiles
of methionine and homocysteine mathematically, and
the elevated homocysteine levels were predicted for
repeated high methionine ingestion. Thus, we confirmed
the clinical importance of diet regulation in diabetic
patients, for maintaining homocysteine levels within the
normal range.
A prior study showed that Tmax of homocysteine
decreased and Cmax increased in ZDF rats relative to
normal rats, which may have resulted in homocysteine
levels in the terminal phase being lower in ZDF rats than
in the controls [14]. It seemed that the metabolism of
homocysteine was upregulated under diabetic conditions
[22]. More rapid transformation of methionine to homo-
cysteine was related to rapid systemic distribution of
homocysteine in patients of high-glucose status. The
increased distribution of homocysteine during the initial
phase was characterized by increased SAAH enzyme
activity [23], as well as by higher protein levels in ZDF
rats than in the controls [14]. The KSH value of ZDF rats
was higher than that of controls, which meant that
upregulation of the insulin-signaling pathway induced
the increased SAHH activity [23]. In addition, our model
Table 1 Final estimated MMC model parameters
Parameters Control rats ZDF rats IIV
(%)Estimated value RSE (%) Estimated value RSE (%)
KCM (hr
− 1) 0.13 16.8 0.13 16.8 –
KMC (hr
−1) 0.0629 – 0.0629 – –
KMS (hr
−1) 0.605 9.5 0.605 9.5 –
KSS (hr
−1) 3220 – 3220 – –
KEL (hr
−1) 0.245 – 0.245 – –
Vc (L/kg) 0.15 – 0.15 – –
KSH (hr
−1) 11.6 20.5 13.5 106.6 –
KHM (hr
−1) 30.7 31.1 2.54 14.7 70.1
KHC (hr
−1) 11.1 4.8 0.52 668.9 –
KHP (hr
−1) 142 18.5 20.4 29.7 45.4
KPH (hr
−1) 5.13 10.4 0.032 16.0 –
ZDF zucker diabetic fatty, IIV inter-individual variability, RSE relative standard error,
KCM & KMC inter-compartment rate constant between peripheral and methionine
compartment, KMS rate constant from methionine to S-adenosylmethionine, KSS rate
constant from S-adenosylmethionine to S-adenosyl homocysteine, KEL elimination rate
constant, Vc apparent volume of distribution of peripheral compartment, KSH rate
constant from S-adenosylhomocysteine to homocysteine, KHM rate constant from
homocysteine to methionine, KHC rate constant from homocysteine to cysteine, KHP &
KPH inter-compartment rate constant between homocysteine and
peripheral compartment
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Fig. 2 Visual predictive check (n = 1000) results of final Mechanistic Methionine Cycle (MMC) model: methionine changes in (a) control rats and
(b) ZDF rats, and homocysteine changes in (c) control rats and (d) ZDF rats
Fig. 3 Plasma methionine levels of 1000 simulated subjects in (a) control rats and (b) ZDF rats, homocysteine levels of same subjects in (c) control rats
and (d) ZDF rats
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showed that elevated levels of enzymes catalyzing homo-
cysteine production and recycling to methionine, corre-
sponding with previous studies conducted using diabetic
in vivo rat models [13, 24]. Among all catalyzing
enzymes, BHMT played a significant role in catalyzing
remethylation of homocysteine to methionine. In the
early phase, BHMT activity was elevated under diabetic
conditions, as a result of increased levels of mRNA
encoding the enzyme. Thus, homocysteine was rapidly
reduced, accompanied by remarkable reductions in the
hepatic concentrations of betaine [24]. However, the
catalyzing rate of homocysteine gradually decreased as
betaine was depleted by the activation of BHMT in
terminal phase [25]. Consequently, an accumulation of
homocysteine occurred. Previously, we described how
KHM and KHC value were lower in ZDF rats than in
controls. On the basis of the calculated accumulation
factor, we predicted that blood homocysteine levels
would rise about three-fold after administration of
methionine on three-times per day over 60 days (a total
of 180 occasions). Furthermore, the decline in KHC was
associated with the decrease in the level of CβS, which is
predominantly associated with the trans-sulfuration
pathway [18]. A previous study revealed that hydrogen
sulfide (H2S) signaling was impaired under diabetic con-
ditions, which can contribute to mediating a reduction
in CβS activity [26]. From these MMC modeling results,
we confirmed that the metabolisms of homocysteine
under diabetic conditions were different than those
under normal conditions.
Subsequently, we explored the influence of a high-
methionine diet on homocysteine levels in T2DM rats, on
the basis of our model. The methionine dose was deter-
mined based on previous reports that have evaluated a
high-dose methionine diet in rats. Yagisawa M et al.
injected with methionine at a dose of 0.67 mmol/kg as a
high-dose methionine diet in rats for estimating the influ-
ence of betaine on cardiovascular diseases. In the study of
Cao Y et al., rats were treated with saline and intravenous
high-dose methionine (0.8 mmol/kg) to generate hyperho-
mocysteinemia model. The methionine dose was equiva-
lent to the human dose of 0.12 g/kg by scaling the body
size, which was higher dose used in Haulrik N et al. study
[27]. The data obtained after repeated methionine admin-
istrations over 2 months showed that homocysteine
concentrations were higher in those with diabetes, regard-
less of individual differences in the enzymes of the MMC.
The greater accumulation ratio of homocysteine with
high-dose methionine led to a greater increase in the AUC
of homocysteine, in the ZDF rats compared to the con-
trols. This may imply an increased risk of hyperhomocys-
teinemia in diabetic patients. These results are consistent
with those of previous studies that used protein-rich or
high-fat diets. High amount of methionine intake induced
more efficient homocysteine metabolism, explained by the
adaptive activation of enzymes involved in the methionine
cycle [27, 28]. Another study found that protein-rich
breakfasts and dinners triggered acute diphasic changes in
plasma methionine and homocysteine concentrations
[29]. Thus, in diabetic patients, a high-methionine diet
can induce significant variation in methionine metab-
olism, which is associated with an increased risk of
vascular complications.
This mathematical approach is both useful and neces-
sary when attempting to identify modes of regulation of
complex metabolic systems and to predict changes in
methionine and homocysteine profiles affected by various
factors that cannot be investigated in the lab. Neverthe-
less, our study had certain limitations. First, the model did
not evaluate clinical factors other than disease status. As
the data were obtained in a previous well-controlled
experiment using a rat model, clinical diversity was low
and inter- and intra-subject variabilities could not be con-
sidered. In addition, the simulation results were analyzed
by direct extrapolation from in vivo rat data to humans.
However, it has been demonstrated that the several
enzymes influencing plasma homocysteine profiles are
similar in the rat and human [30].
Conclusion
In conclusion, we found that methionine-rich foods
elevated both methionine and homocysteine levels in
ZDF model, regardless of individual differences in
enzymes of the MMC cycle. It is well known that
high homocysteine levels are significantly associated
with both atherosclerosis and vascular disease, by
inhibiting vascular endothelial cell growth [21], and
hyperhomocysteinemia is considered to be a bio-
marker of atherosclerosis in mammals [31, 32],
especially in patients with T2DM than those without
[9]. Thus, it is important that T2DM patients avoid
high-methionine diets to regulate their homocysteine
levels within the normal range, and to prevent cardio-
vascular disease and mortality.
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